TMCnet News
MicroCapProfiler.com: NeoMedia Technologies, Inc. (OTCBB: NEOM), PolyMedix, Inc. (OTCBB: PYMX), MusclePharm Corporation (OTCBB: MSLP): Join FREE Today & Get Our Next Big Pick!(M2 PressWIRE Via Acquire Media NewsEdge) To subscribe to this FREE service, visit the Stock Report home page at: http://www.MicroCapProfiler.com and sign up FREE for "Daily Stock Alerts!" _______________________________________________________________________ Get Top Penny Stock Pick Alerts Free at: http://www.MicroCapProfiler.com NeoMedia Partners with Global IP Law Group for Patent Monetization Strategic Alliance with Top IP Law Firm Designed to Increase Value of NeoMedia's Patent Portfolio ATLANTA --9-19-2011 -- NeoMedia Technologies, Inc. (OTC BB: NEOM.OB), the global leader in mobile barcode scanning solutions, today announced a new partnership with Global IP Law Group(giplg.com), an elite law firm focused on unlocking the financial potential of intellectual property (IP). The alliance has been planned to assist in the monetization and enforcement of NeoMedia's IP and extricate further value from its large patent portfolio. NeoMedia's IP portfolio currently consists of over sixty issued and pending patents. "Global IP Law Group is a leader in IP monetization and partnering with them is an important step forward in driving value for our IP portfolio. This partnership allows us to realize the potential of our efforts and innovations, further strengthening our existing partnerships. Mobile has become a key media channel for brands and agencies globally, and our IP and technology has been a key component," said Laura Marriott, Chief Executive Officer of NeoMedia Technologies, Inc. Global IP concentrates on all aspects of monetizing intellectual property (particularly patents) through sales, licensing, and litigation. Over the last five years, the partners of Global IP have obtained nearly US $5 billion in closed and pending IP transactions, licenses and settlements for clients-far more than any other IP-focused firm in the world. "NeoMedia's strong and valuable IP portfolio is a great addition for our organization. In recent years we have secured significant revenue for our clients, and we look forward to working closely with NeoMedia to help them reap the financial benefits of its IP portfolio," said Ragnar Olson, Global IP Law Group. To learn more about NeoMedia's product portfolio, visit www.neom.com. About NeoMedia: NeoMedia Technologies, Inc. is the global market leader in 2D mobile barcode technology and infrastructure solutions that enable the mobile barcode ecosystem world-wide. Its technology platform transforms mobile devices with cameras into barcode scanners, enabling a range of practical and engaging applications including consumer oriented advertising, mobile ticketing and couponing, and business-to-business commercial track and trace solutions. NeoMedia's suite of products, services and extensive IP portfolio means it is the only provider able to offer customers a comprehensive end-to-end mobile code solution. NeoMedia's current customers include handset manufacturers, platform providers, brands and agencies looking to offer pioneering mobile barcode solutions to their customer base. NeoMedia's product portfolio includes: mobile barcode management & infrastructure solutions, barcode reader solutions, Mobile Coupon & Affiliate Marketing, Mobile Ticketing & POS Integration and IP Licensing. Learn more at www.neom.com or visit us at one of the following online destinations: LinkedIn: http://www.linkedin.com/company/neomedia-technologies Twitter: http://twitter.com/neomediainc About Global IP Law Group, LLC Global IP Law Group, LLC is a law firm based in Chicago, Illinois with affiliates in London, Auckland, and Seoul. Global IP assists clients in monetizing patents through sales, licensing, and litigation. The firm advised Nortel Networks through the monetization process of Nortel's more than 6,000 patents, which culminated in pending sale to a consortium including Apple, Microsoft, RIM, Sony and Ericsson for $4.5 billion. ___________________________________________________________________________ PolyMedix Presents Antibiotic Data in Oral Session at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Oral Session Focused on New Antimicrobial Agents in Development RADNOR, Pa., Sept. 19, 2011 -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, today announced the presentation of data at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago on September 17 and 18, 2011. PolyMedix was selected by ICAAC as part of a select group to participate in a special oral session that featured new antimicrobial agents in development. In addition, PolyMedix presented data, in poster format, on both its lead defensin-mimetic antibiotic compound, PMX-30063 and other new antibiotic compounds. In an oral poster preview session on Saturday, September 17, Dr. Richard Scott, Vice President of Research at PolyMedix, presented data on PolyMedix's new class of defensin-mimetic antibiotics, including PMX-30063. Dr. Scott's presentation highlighted significant attributes of PolyMedix's defensin-mimetic antibiotics including, the novel mechanism of action which mimics innate human immunity and makes bacterial resistance unlikely to develop, the unique resistance profile which exerts bactericidal activity against bacteria that are resistant to conventional antibiotics, the basic principles underlying the antimicrobial activities of the defensin-mimetics, the spectrum of activity against Gram-positive and Gram-negative pathogens, and the wide selectivity for bacteria over mammalian cells. In addition, pre-clinical data showing activities against biowarfare pathogens and MRSA biofilms were presented. Dr. Scott closed his presentation with a discussion on PMX-30063,PolyMedix's lead antibiotic compound currently in a Phase 2 clinical trial. PolyMedix also presented the following pre-clinical and clinical data in poster form: o "Safety and Multiple Dose Pharmacokinetics of Intravenous PMX-30063: A Novel Class of Antibiotics" PolyMedix conducted a Phase 1 trial to evaluate the safety and pharmacokinetics of multiple doses of PMX-30063 in male and female healthy subjects. In this study, PMX-30063 was administered up to 14 days at the highest dose that is currently being tested in an ongoing Phase 2 clinical trial. The results showed dose-dependent pharmacokinetics consistent with linear behavior and no apparent gender effects. Safety parameters, such as paraesthesia and increases in blood pressure and heart rate, were transient and fully reversible following drug discontinuation. In conclusion, pharmacokinetics and safety observations from this study support once daily dosing for five days as is being conducted in an ongoing Phase 2 clinical trial. o "Activity of Nonpeptidic Mimics of Host Defense Proteins against Bacillus anthracis in a Mouse Aerosol Challenge Model" PolyMedix tested several of its defensin-mimetic antibiotic compounds that are well-tolerated and exhibit low cytotoxicity, including one that is a close structural analog of PMX-30063, in an animal model against Bacillus anthracis, the bacteria that causes anthrax. The results identified lead compounds that were highly active in this stringent model when treatment was initiated as late as one day following infection. These results support further study of anti-biowarfare indications and other related infections. The above mentioned presentations are available on the Company's website athttp://www.polymedix.com/presentations.php: About ICAAC The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is an annual event hosted by the American Society for Microbiology and is the premier meeting on infectious diseases. For the past 51 years, the meeting has presented late-breaking scientific information featuring physicians, researchers and other healthcare professionals from around the world fostering solutions for the problem of infectious disease. About PolyMedix, Inc. PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has a pipeline of novel cardiovascular and infectious disease product candidates, all of which were internally developed using proprietary computational drug design technologies. The lead compound in PolyMedix's cardiovascular program is PMX-60056, which is designed to modulate coagulation and mitigate bleeding in certain interventional cardiology procedures, such as Percutaneous Coronary Intervention (PCI), and emergency situations. PMX-60056 has met safety and efficacy endpoints in four clinical trials conducted to date demonstrating clinical proof of concept. PMX-60056 is currently in a Phase 2 clinical trial in patients undergoing PCI. The lead compound in PolyMedix'sinfectious disease program is PMX-30063, a new class of antibiotic - a defensin-mimetic - designed to mimic first-line human innate immunity, or host defense proteins. This innovative approach utilizes the same mechanism of action that evolved in nature which higher life forms use to protect themselves from bacteria. Having the same mechanism of action as the host defense proteins, PMX-30063 is designed to directly address one of the most significant issues in infectious disease today - drug resistance, which is believed to be much less likely to develop with PMX-30063. PMX-30063 is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph aureus bacteria, including methicillin-resistant Staph aureus (MRSA). PolyMedix is also leveraging its antimicrobial expertise with the PolyCides, antimicrobial additives to materials, such as cosmetics, plastics and textiles, to create self-sterilizing products and surfaces. For more information, please visit our website at www.polymedix.com. This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix's need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix'scompounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. _______________________________________________________________________ MusclePharm Strengthens Management Team Adding John H. Bluher as COO and EVP DENVER, Sept. 20, 2011 -- MusclePharm Corporation (OTCBB: MSLP), an expanding U.S. nutritional supplement company ("MusclePharm" or the "Company"), is pleased to announce John H. Bluher has been named Chief Operating Officer and Executive Vice President for MusclePharm Corporation("MSLP"). In announcing the new appointment, MusclePharm CEO Brad Pyatt said, "As COO, John brings us exceptional depth and balance. His broad range of experience with public companies, boards and financial structuring in addition to mergers and acquisitions will prove helpful as we are positioning MusclePharm for continued growth and profitability in 2012. He has proven abilities to realize the potential of an organization while rationalizing operational cost. We are extremely excited about how John will contribute to the further strengthening of MusclePharm's leadership position and growth prospects." Mr. Bluher will immediately join the Executive Committee and the MSLP Board of Directors in October 2011. As COO, he reports to Mr. Pyatt and has responsibility for functional management and day-to-day operations. His long-range goals are to help with budgeting, managing MSLPs capital structure, structure departments as the company grows, develop control processes, and assist in developing supply chain management and inventory controls. Working closely with Mr. Bluher, Mr. Pyatt will now have time to focus on longer-range strategies, business development, extending the branding and marketing opportunities for MusclePharm. Finance, Legal, Operations, Investor Relations, Public Relations, and Administration report to Mr. Bluher. Mr. Bluher has been working as a consultant to MSLP for the past three months. Mr. Bluher said: "I am excited for the opportunity to come into MusclePharm at such an important time for this young company. The company is growing at a tremendous pace and with the brand recognition accelerating, Brad felt that he needed someone focused full time on the internal controls, budgets, and financial and capital requirements of the company. Brad has aggressively built the brand and grown the company with innovative products, I will be focusing on building on his success so we can provide a return to our equity investors." Mr. Bluher has significant experience working with corporate structuring, corporate boards and committees, risk management, and public company corporate governance. He has 20 years of experience working in financial services public companies as Chief Legal Officer, General Counsel, Director of Risk, and Chief Compliance Officer. Most recently he was Chief Legal Officer at Neuberger Berman and managed the sale of this company out of the Lehman Brothers estate. He was also General Counsel of the Investment Management Division of Lehman Brothers, Inc. His experience also includes negotiating transactions and purchases, and sales of assets and properties on a global basis. He has deep experience in creating and implementing corporate governance plans, working in the corporate board room, and as director of risk, developing internal audit programs and insurance programs for public companies. He has served on the boards of ICI Mutual Insurance Company, the NASDAQ Chairman's Advisory Board,Cherry Hills Founders Group, Inc., and the University of Wyoming, College of Law Advisory Board. Mr. Bluher is currently on the Board of Targeted Medical Pharma, Inc., Safe Communications, Inc. and University of Wyoming Foundation Board. About MusclePharm Corporation Headquartered in Denver, Colorado, MusclePharm is a healthy life-style company that develops and manufactures a full line of NSF and Informed Choice approved nutritional supplements that are free of banned substances. Based on years of research at the MusclePharm Sports Science Center, the products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues including the National Football League, Mixed Martial Arts, and Major League Baseball. The Company's products address all categories of an active lifestyle, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe, and Vitamin World. MusclePharm products are also sold in over 100 online stores, including bodybuilding.com, Amazon.com and Vitacost.com. For more information, please visit www.musclepharm.com. Forward Looking Statements The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. ___________________________________________________________________________ Get Top Penny Stock Pick Alerts Free at: http://www.MicroCapProfiler.com About MicroCapProfiler.com www.MicroCapProfiler.com is a premier source for microcap research - providing a wide range of due diligence and investment insight on stocks that trade on OTC, OTCBB, NYSE, NASD, and AMEX exchanges, and are mostly referred to as "penny stocks". These are stocks that trade under $5 a share and offer the GREATEST potential return on your short or long term investment. MicroCapProfiler.com Investment Report primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market place. As every investor knows, timing in the market is critical! To receive our FREE comprehensive newsletter, please visit http://www.MicroCapProfiler.com We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by MicroCapProfiler.com. Please be advised that the information provided May or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. To view a complete disclaimer, visit: http://MicroCapProfiler.com/disclaimer.html To feature your publicly traded company in our alerts, email us at: [email protected] Let MicroCapProfiler.com help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at: [email protected] CONTACT: CONTACT: Micro Cap Profiler Tel: +1 321 439 1823 e-mail: [email protected] WWW: http://www.MicroCapProfiler.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). (c) 2011 M2 COMMUNICATIONS |